Aileen Alviar, NP
Nurse Practitioner · Fremont
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Aileen Alviar’s office to ask if they take your plan before you enroll.
Original Medicare doctor bills
$4,325
Medicare paid this office $4,325 for 59 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 35 | $2,260 | $58 |
Who their Medicare patients are
59 Original Medicare patients in 2024. Average age 79 · Under 65 0% · 85 and older 27% · Women 56% · Health risk score 1.55. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 75% · Chronic kidney disease 47% · Coronary heart disease 41% · Depression 41% · COPD 32% · Atrial fibrillation 31% · Diabetes 25% · Heart failure 22%.
The office billed $16,070, Medicare allowed $6,827 and paid $4,325; for 137 services of 30 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Drugs they prescribed that Part D paid
$7,129
Pharmacies billed $7,129 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 174) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
147 generic and fewer than 11 brand-name prescriptions · $7,129 in drug cost · 30 antibiotic prescriptions to 30 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Amlodipine Besylate | 16 | $116 | $7 |
| Alendronate | 11 | $20 | $2 |
Year by year
| 2024 | 174 | 75 | 0% (0) | None | $7,129 |
| 2023 | 20 | None | 0% (0) | None | $1,218 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Money from drug and device companies
$100 in 2025
| 2025 | 5 | 5 | None | $100 |
| 2024 | 8 | 15 | None | $410 |
| 2023 | 1 | 1 | None | $114 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Merck Sharp & Dohme | Verquvo | $24 | 1 payment
|
| Novartis Pharmaceuticals | Leqvio | $24 | 1 payment
|
| AngioDynamics | Alphavac | $19 | 1 payment
|
| Pfizer | Vyndaqel | $18 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $14 | 1 payment
|
See all 5 published payments
| Novartis Pharmaceuticals | Meals · 2025-09-10 | Leqvio | $24 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-09-09 | Jardiance | $14 |
| Merck Sharp & Dohme | Meals · 2025-09-08 | Verquvo | $24 |
| Pfizer | Meals · 2025-09-04 | Vyndaqel | $18 |
| AngioDynamics | Meals · 2025-09-03 | Alphavac | $19 |
See earlier years (2024, 2023)
2024: $410
| GlaxoSmithKline | Arexvy | $146 | 2 payments
|
| Lilly USA | Mounjaro | $88 | 4 payments
|
| Novo Nordisk | Rybelsus | $52 | 3 payments
|
| Exact Sciences | Cologuard Collection Kit | $45 | 2 payments
|
| Phathom Pharmaceuticals | Voquezna | $22 | 1 payment
|
| Abbvie | Vraylar | $20 | 1 payment
|
| Esperion Therapeutics | Nexletol | $19 | 1 payment
|
| Pfizer | Eliquis | $19 | 1 payment
|
2023: $114
| AstraZeneca Pharmaceuticals LP | Breztri | $114 | 1 payment
|
Professional record
- NPI
- 1205562246
- Licence
- CA 95021794, FL APRN11019337
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 9460 N Name Uno Ste 110, Gilroy, CA, 95020
- NPI first listed
- 2022-07-30
- NPI last updated
- 2026-03-01
- NPI record certified
- 2026-03-01
This is when the NPI record was last certified, not a medical board exam.